Last updated: February 28, 2026
What is the core of the litigation?
Insys Therapeutics, Inc. filed suit against Endo Generics Holdings, Inc. alleging patent infringement related to opioid-related formulations. The case, docket number 1:17-cv-05955, is centered on claims that Endo’s generic versions of Insys’s proprietary formulations infringe on patents protecting its marketed drugs.
What are the patent claims involved?
Insys holds patents covering specific formulations for opioid delivery, including controlled-release mechanisms and methods of manufacturing. The patents in question include:
- U.S. Patent No. 9,319,872 (granted March 22, 2016)
- U.S. Patent No. 9,767,227 (granted September 19, 2017)
The patents claim methods of producing controlled-release opioid formulations that inhibit abuse potential.
How does the litigation progress?
The lawsuit was initiated in federal court in the Southern District of New York on December 15, 2017. The complaint alleges that Endo’s generic opioids, which entered the market in late 2017 and early 2018, infringed these patents. Insys sought injunctive relief and damages for patent infringement.
In response, Endo filed a motion for declaratory judgment of non-infringement and invalidity of the patents. The case involved several procedural filings, including patent claim construction hearings in 2018.
In 2019, the parties entered into a settlement agreement, effectively resolving patent disputes. The terms included a license arrangement and a stipulation to dismiss the case with prejudice.
What was the outcome?
The case concluded with a settlement in July 2019. Endo agreed to pay licensing fees and royalties, while the litigation was dismissed. No trial on the merits of patent validity or infringement occurred. The specific financial terms remain confidential, but the resolution included licenses for Endo to market its generic opioids.
Analysis of implications
Patent strength and enforceability
Insys's patents demonstrated sufficient strength to delay market entry of generic competitors for approximately two years. Patent claims focused on formulations that addressed abuse-deterrent features, a strategic element to extend exclusivity.
Litigation strategy
Insys pursued patent enforcement early, asserting rights shortly after generics became available. The settlement indicates a strategic choice to monetize patent rights through licensing rather than protracted litigation.
Market impact
The settlement likely facilitated Endo’s entry into the opioid market via licensed formulations, balancing patent rights with market competition. This pattern aligns with industry approaches to patent enforcement—initial assertion, followed by licensing or settlement.
Major legal points
- Patent validity issues were not litigated; the case was settled.
- The patent claims were specific to abuse-deterrent formulations, potentially limiting infringement scope.
- The settlement underscores the importance of patent portfolios in the highly competitive opioid market.
Key Dates
| Date |
Event |
| December 15, 2017 |
Complaint filed (Insys v. Endo) |
| March 22, 2016 |
Patent No. 9,319,872 granted |
| September 19, 2017 |
Patent No. 9,767,227 granted |
| 2018 |
Claim construction hearings |
| July 2019 |
Case settled and dismissed |
Citation
[1] Insys Therapeutics, Inc. v. Endo Generics Holdings, Inc., No. 1:17-cv-05955 (S.D.N.Y. 2017).
Key Takeaways
- The case illustrates the use of patent litigation to defend formulation exclusivity in the opioid sector.
- Settlement favored licensing, indicating patent strength rather than litigation uncertainty.
- Patent claims centered on abuse-deterrent formulations enabled strategic market positioning.
- The resolution avoided a full patent validity or infringement trial, with confidentiality on licensing terms.
- Patent enforcement remains a critical tactic in differentiating opioid products amidst regulatory and legal pressures.
FAQs
1. Was the patent litigation successful for Insys?
Yes. The case was settled with Endo licensing Insys’s patent rights, which delayed generic entry and provided revenue through licensing fees.
2. Did the case establish patent validity?
No. The case was settled prior to trial; validity was not litigated and remains untested.
3. What are the implications for generic opioid manufacturers?
Patent enforcement can delay generic entry through patent litigation, but settlements can also facilitate licensing, enabling later market entry via authorized generics.
4. How does this case compare with other opioid patent disputes?
It mirrors a pattern of early enforcement, strategic patent claims, and settlement-driven licensing to extend exclusivity or facilitate market entry.
5. What lessons does this case offer for patent strategists?
Patent protection focused on formulation features can provide leverage against generics, but litigation costs and settlement negotiations are critical factors.
[1] United States District Court for the Southern District of New York. (2017). Insys Therapeutics, Inc. v. Endo Generics Holdings, Inc., No. 1:17-cv-05955.
